Please assess the completion status of the following clinical trial:

Trial Title: Surfactant Versus Nasal Continuous Positive Airway Pressure (nCPAP) for Respiratory Distress Syndrome in the Newborn ≥ 35 Weeks of Gestation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age between 35 and 41 weeks of gestation~* \< 24 hours of life~* Nasal Continuous Positive Airways Pressure (nCPAP) for more than 1 hour~* FiO2 ≥ 30% with nCPAP and a target post-ductus arteriosus SpO2 \>92%~* Written consent of the parents~Exclusion Criteria:~* FiO2 \> 60% with nCPAP, ou FiO2 \> 40% for 3 consecutives hours whatever the respiratory support~* Life threatening congenital pathology~* Congenital cardiopathy (except patent ductus arteriosus)~* Shock defined as systemic hypotension (mean blood pressure \<10th percentile of the normal range for birth weight and postnatal age) with at least 3 of the following criteria for decrease perfusion: 1) tachycardia (heart rate \> 160 beats/min); 2) abnormal peripheral pulses; 3) modified extremities coloration; 4) prolonged capillary refill time \> 3 seconds; 5) urine output \< 1 ml/kg/h~* Blood gas pH \< 7.19 and / or PCO2 \> 65 mmHg~* Apgar score ≤ 3 at 5 minutes of life

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: f

Study Arms:
- Early strategy (Type: EXPERIMENTAL): Intratracheal poractant alpha (Curosurf®) after tracheal intubation
- Delayed strategy (Type: ACTIVE_COMPARATOR): Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 \> 60%

Based on this trial design, predict the completion outcome and termination type (if applicable).